Aurobindo Pharma 's wholly owned subsidiary CuraTeQ Biologics Private Limited has achieved a significant regulatory milestone with Health Canada's approval of its bevacizumab biosimilar. The company formally announced on May 1, 2026, through a regulatory filing that it received Notice of Compliance (NOC) from Health Canada's Biologics and Radiopharmaceutical Drugs Directorate (BRDD) for Bevqolva™, marking another key market entry for the biosimilar product used in cancer treatment.

Regulatory Approval Details

Health Canada's NOC represents formal marketing authorization granted after a successful regulatory review process. The approval confirms that Bevqolva™ meets stringent regulatory standards for safety, efficacy, and quality, demonstrating comparability to the reference biologic drug under the Food and Drug Regulations.

Product Profile and Mechanism

Bevacizumab is a humanized monoclonal antibody that functions as an angiogenesis inhibitor. The drug works by blocking vascular endothelial growth factor A (VEGF-A), which plays a crucial role in the formation of new blood vessels. This mechanism of action effectively slows tumor vascular growth and provides therapeutic benefits in treating multiple cancer types, including colorectal and lung cancers.

The originator product, Avastin, is marketed by Roche/Genentech and represents a significant market opportunity for biosimilar competitors. Bevqolva™ offers healthcare systems and patients an alternative treatment option with comparable efficacy and safety profiles.

Global Market Expansion

CuraTeQ Biologics has been systematically expanding Bevqolva™'s global presence across multiple regulatory jurisdictions. The company achieved notable success in 2025 when it secured marketing authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) and successfully launched the product commercially for patients across the United Kingdom.

Pipeline and Future Prospects

Beyond Bevqolva™, CuraTeQ Biologics maintains an active biosimilar development pipeline with Health Canada. The company currently has two additional biosimilar applications under review by the Canadian regulatory authority, indicating continued expansion of its product portfolio in the Canadian market.

The European Medicines Agency review through the Committee for Medicinal Products for Human Use (CHMP) represents another significant opportunity for market expansion, potentially providing access to the broader European Union market for Bevqolva™.

aurobindo pharma has announced the retirement of Mr. N. Ravi Kiran, Chief Business Officer, Emerging Markets, from the company. The retirement will be effective from the close of business hours on April 30, 2026. This disclosure was made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company submitted the information to both the National Stock Exchange of India Limited and BSE Limited as part of its compliance with the SEBI Listing Regulations. The announcement was digitally signed by B Adi Reddy, Company Secretary, on April 30, 2026.

Details of the Management Change

The company provided specific details regarding the management change in an annexure to the disclosure. The key particulars are outlined below:

The retirement pertains specifically to Mr. N. Ravi Kiran's role as Chief Business Officer, Emerging Markets, which is classified as a senior management position within the organization. The company has confirmed that all required disclosures under Regulation 30 have been provided to the stock exchanges.

Aurobindo Pharma Limited, headquartered in Hyderabad, Telangana, operates with its corporate office at Galaxy, Hyderabad Knowledge City, and registered office at Maithrivihar, Ameerpet. The company can be contacted through its official website at www.aurobindo.com or via email at info@aurobindo.com .